Janux Therapeutics (JANX) Superinvestor holders
12 of the superinvestors we track hold Janux Therapeutics (JANX) in their latest 13F filings, $86M in total.
Summary
The largest holder is Steve Cohen (Point72 Asset Management), with $31M, 0.0% of the portfolio.
In their latest quarter: 3 opened a new position, 4 added, 3 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Steve Cohen Point72 Asset Management |
Added | 1,993,837 | $31M | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Added | 1,207,250 | $19M | 0.0% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 1,096,509 | $17M | 0.0% | Q2 2026 |
| Wilmot Harkey Nantahala Capital Management |
Held | 809,914 | $12M | 0.8% | Q2 2026 |
| Man Group Man Group plc |
Trimmed | 248,801 | $4M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
New position | 108,077 | $2M | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
New position | 34,320 | $591,000 | 0.0% | Q3 2026 |
| Paul Marshall Marshall Wace |
New position | 32,734 | $502,794 | 0.0% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp |
Trimmed | 28,070 | $431,155 | 0.0% | Q2 2026 |
| Didric Cederholm Lion Point Capital |
Held | 19,000 | $291,840 | 1.4% | Q2 2026 |
| Alan Howard Brevan Howard |
Trimmed | 16,204 | $248,893 | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Added | 8,250 | $126,720 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 11 |
| Q1 2026 | 10 |
| Q4 2025 | 8 |
| Q3 2025 | 4 |
| Q2 2025 | 5 |
| Q1 2025 | 6 |
| Q4 2024 | 11 |
| Q3 2024 | 6 |
Questions about Janux Therapeutics
Which superinvestors own Janux Therapeutics?
12 of the superinvestors we track hold Janux Therapeutics (JANX) in their latest 13F filings, $86M in total. Steve Cohen, Two Sigma, David Shaw, Wilmot Harkey, Man Group, Cliff Asness.
Who is the largest superinvestor holder of JANX?
The largest holder is Steve Cohen (Point72 Asset Management), with $31M, 0.0% of the portfolio.
From Janux Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.